Latest news with #OCT
Korea Herald
23-05-2025
- Business
- Korea Herald
Intalight™ Receives CE Mark for Its Progressive DREAM OCT™ Swept Source Imaging
SAN JOSE, Calif. and SHANGHAI, May 15, 2025 /PRNewswire/ -- Intalight ™, a company that develops advanced ophthalmic technologies and a leader in Optical Coherence Tomography (OCT) today announced it has received CE mark for its DREAM OCT ™ platform. The CE mark serves as approval by the European Union (EU) to commercialize DREAM OCT, the newest version of OCT. DREAM stands for: Deep imaging depth, Rapid sweeping speed, Extensive scan range, Accurate results, and Multimodal imaging capabilities. The imaging platform provides the highest quality OCT images currently on the market. "Intalight is incredibly proud to receive CE mark approval in Europe for our DREAM OCT," said Intalight chairman and Founder, Shawn Peng. "This achievement allows us to provide ophthalmologists in Europe with state-of-the-art technology that delivers improved results for their patients." DREAM OCT is able to cover an ultrawide field single scan which delivers a 130° OCTA image. DREAM OCT ™ swept-source 12 mm super-depth scanning allows superior imaging of the choroid and retina, and a large portion of the vitreous space. The super-depth anterior scanning capabilities achieves 16.2 mm (in air), allowing for the complete anterior segment from the cornea to the anterior part of the vitreous to be scanned in only one scan. The longer wavelength allows for superior penetration through opacities in either lens or vitreous. "Over the past few years, we've heard from eye care professionals that they need a solution that gets them over the imaging finish line with speed, accuracy and depth," said Intalight CEO and Co-Founder, Bing Li. "DREAM OCT delivers a full set of imaging modalities for the most challenging clinical and research applications for the retina and outperforms everything else HCP's know." Using ultra-wide swept-source technology, DREAM OCT was developed to address the needs of retina specialists, comprehensive ophthalmologists and their patients with highly-detailed imaging capabilities for improved care and results. Currently, more than 160 peer-reviewed papers have utilized findings from DREAM OCT devices. "This is such exciting news for Intalight that there's no more waiting in Europe, and we look forward to being able to provide this innovative solution in the US," remarked Intalight Chief Commercial Officer, Joe Garibaldi. "We look forward to continuing to grow our prestigious network of global institutions and ophthalmologists with our recent CE approval and eventually our FDA approval." As the clinically validated leader of ultra-wide field OCTA, Intalight is currently collaborating with the top retina academic institutions and retina private practices in the United States, Europe, and Asia. About Intalight Intalight Inc. was founded by a group of scientists and industry veterans of Silicon Valley with a core mission to develop the most advanced ophthalmic technologies. There are now three sites in Silicon Valley, Shanghai, and Luoyang. Intalight's Swept-Source Optical Coherence Tomography (OCT) device combines Deep imaging depth, Rapid sweeping speed, Extensive scan range, Accurate lesion detection and Multimodal imaging capabilities, and is abbreviated as DREAM OCT ™. The powerful imaging device has become an indispensable tool for many ophthalmologists in not only their daily clinical use but also their exploration of the research frontiers. To learn more about Intalight and DREAM OCT, please visit our website at and follow us on LinkedIn and Facebook.
Yahoo
23-05-2025
- Business
- Yahoo
Perimeter Partners with Intermountain Health to Study the Potential Clinical, Social and Economic Benefits of Using OCT and AI to Reduce Cancer Reoperations
TORONTO and DALLAS, May 23, 2025 /CNW/ - Perimeter Medical Imaging AI, Inc. (TSXV: PINK) (OTCQX: PYNKF) ("Perimeter" or the "Company"), a commercial-stage medical technology company, is pleased to announce that it has entered into a Development Support Agreement ("DSA") with Salt Lake City-based Intermountain Health, the largest nonprofit health system in the Intermountain West. This agreement creates the framework for the two organizations to partner on a number of future studies evaluating the potential value of using Perimeter's OCT and collecting additional data to support the continued development of the Company's artificial intelligence ("AI") algorithms. In the first of these studies, Intermountain Health will support a retrospective analysis of population level reoperation rates and incremental healthcare costs associated with reoperation for patients who underwent initial breast-conserving surgery ("BCS") at select hospital sites. "At Intermountain Health, we understand the significance of innovation, like Perimeter's proprietary wide-field OCT interoperative margin assessment technology, that has the potential to optimize surgical oncology outcomes for patients, and support efficient delivery of care," said Teresa Reading, MD, medical director, breast surgery, Canyons Region at Intermountain Health who is involved with the clinical use of this technology. "We look forward to initiating this first study among our BCS patient population, as well as potentially expanding to other tissue types in the future." "Intermountain Health is a fully integrated healthcare delivery system. It shares our commitment to improving both the patient and provider experience through innovation. And with its own health plan, Intermountain Health is uniquely positioned to evaluate the total cost of cancer reoperations - not only to the patient, but also to the payer," commented Adrian Mendes, Perimeter's Chief Executive Officer. "We are excited about how this partnership can help shape our commercial and market access strategies as we work to advance not only our next-generation, AI-enabled Perimeter OCT system for use during BCS through the FDA PMA approval process, but also as we look to expand into other tissue types beyond breast." About Intermountain Health Headquartered in Utah with locations in six states and additional operations across the western U.S., Intermountain Health is a not-for-profit health system with 33 hospitals, approximately 400 clinics, medical groups with some 4,600 employed physicians and advanced care providers, a health plans division called Select Health with more than one million members, and other health services. Helping people live the healthiest lives possible, Intermountain Health is committed to improving community health and is widely recognized as a leader in transforming healthcare by using evidence-based best practices to consistently deliver high-quality outcomes at sustainable costs. About Perimeter Medical Imaging AI, Inc. Based in Toronto, Canada and Dallas, Texas, Perimeter Medical Imaging AI (TSX-V: PINK) (OTCQX: PYNKF) is a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address areas of high unmet medical need. Available across the U.S., our FDA-cleared Perimeter S-Series OCT system provides real-time, cross-sectional visualization of excised tissues at the cellular level. The breakthrough-device-designated investigational Perimeter B-Series OCT with ImgAssist AI represents our next-generation artificial intelligence technology that has recently been evaluated in a pivotal clinical trial, with support from a grant of up to US$7.4 million awarded by the Cancer Prevention and Research Institute of Texas. The company's ticker symbol "PINK" is a reference to the pink ribbons used during Breast Cancer Awareness Month. Perimeter B-Series OCT is limited by U.S. law to investigational use and not available for sale in the United States. Perimeter S-Series OCT has 510(k) clearance under a general indication and has not been evaluated by the U.S. FDA specifically for use in breast tissue, breast cancer, other types of cancer, margin evaluation, and reducing re-excision rates. The safety and effectiveness of these uses has not been established. For more information, please visit Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Forward-Looking Statements This news release contains statements that constitute "forward-looking information" within the meaning of applicable Canadian securities legislation. In this news release, words such as "may," "would," "could," "will," "likely," "believe," "expect," "anticipate," "intend," "plan," "estimate," and similar words and the negative form thereof are used to identify forward-looking statements. Forward-looking information may relate to management's future outlook and anticipated events or results and may include statements or information regarding the future financial position, business strategy and strategic goals, competitive conditions, research and development activities, projected costs and capital expenditures, research and clinical testing outcomes, taxes and plans and objectives of, or involving, Perimeter. Without limitation, information regarding management's views regarding the second quarter, the potential benefits of Perimeter S-Series OCT and Perimeter B-Series OCT and the expected benefits of Perimeter's updated version of its ImgAssist AI are forward-looking information. Forward-looking statements should not be read as guarantees of future performance or results, and will not necessarily be accurate indications of whether, or the times at or by which, any particular result will be achieved. No assurance can be given that any events anticipated by the forward-looking information will transpire or occur. Forward-looking information is based on information available at the time and/or management's good-faith belief with respect to future events and are subject to known or unknown risks, uncertainties, assumptions, and other unpredictable factors, many of which are beyond Perimeter's control. Such forward-looking statements reflect Perimeter's current view with respect to future events, but are inherently subject to significant medical, scientific, business, economic, competitive, political, and social uncertainties and contingencies. In making forward-looking statements, Perimeter may make various material assumptions, including but not limited to (i) the accuracy of Perimeter's financial projections; (ii) obtaining positive results from trials; (iii) obtaining necessary regulatory approvals; and (iv) general business, market, and economic conditions. Further risks, uncertainties and assumptions include, but are not limited to, those applicable to Perimeter and described in Perimeter's Management Discussion and Analysis and Annual Information Form for the year ended December 31, 2024, which are available on Perimeter's SEDAR+ profile at and could cause actual events or results to differ materially from those projected in any forward-looking statements. Perimeter does not intend, nor does Perimeter undertake any obligation, to update or revise any forward-looking information contained in this news release to reflect subsequent information, events, or circumstances or otherwise, except if required by applicable laws. CONTACTS: Stephen Kilmer Investor RelationsDirect: 647-872-4849Email: skilmer@ Adrian MendesChief Executive OfficerToll-free: 888-988-7465 (PINK)Email: investors@ View original content to download multimedia: SOURCE Perimeter Medical Imaging AI Inc. View original content to download multimedia:
India Today
21-05-2025
- Health
- India Today
High blood pressure silently damages your eyes: Know how to catch it early
One of the most common diseases that carries a high burden among the Indian population is hypertension. This non-communicable disease, which is known to show no symptoms, hence its name 'the silent killer', ends up developing into highly serious blood pressure is when the force of blood pushing against the artery wall is too high. For this, the heart has to work harder to pump no treatment is given, hypertension can damage blood vessels throughout the body. Besides leading to health problems like heart disease, stroke and kidney disease, high blood pressure can also damage your vision. "We know that high blood pressure affects the heart, but what we don't realise often is that it can silently damage the eyes and even lead to blindness if left untreated," said Dr. Jay Goyal, Eye Surgeon and Director at Surya Eye Institute. When no treatment is given, hypertension can damage blood vessels throughout the body. () 'In India, about 22.6% of the population has hypertension. This puts a large part of the population at risk for severe vision problems. Thankfully, we now have advanced, non-invasive tools like OCTA and OCT EDI that help us detect early damage in the retina and optic nerve caused by hypertension.'advertisementHOW HIGH BLOOD PRESSURE AFFECTS YOUR EYESWhen high blood pressure damages the small and delicate blood vessels that carry blood to the eyes. This can lead to:Retinopathy: This is damage to the retina, the part of the eye that senses light. It can cause blurred vision, bleeding in the eye, or complete vision loss. People with both diabetes and high blood pressure are at even higher risk. When high blood pressure damages the small and delicate blood vessels that carry blood to the eyes. () Choroidopathy: High blood pressure can lead to fluid build-up under the retina, causing distorted vision or scarring that worsens neuropathy: If blood flow to the optic nerve (which sends visual signals to the brain) is blocked, it can cause nerve damage, bleeding inside the eye, and permanent vision TO CATCH IT EARLY Since high blood pressure often shows no early symptoms, regular health check-ups are to Dr. Goyal, eye specialists now use tests like OCT (Optical Coherence Tomography) and OCTA (Optical Coherence Tomography Angiography) to detect changes in blood flow and signs of early eye damage, even before symptoms appear. Since high blood pressure often shows no early symptoms, regular health check-ups are required. (s) These tests are quick, painless, and non-invasive. Therefore, early detection is crucial. You can reduce your risk of eye damage from hypertension by:Getting your eyes checked regularly, especially if you have high blood pressureEating a balanced diet low in saltExercising regularlyManaging stressTaking prescribed medication to control your blood pressureHigh blood pressure may be silent, but its effects don't have to be. With regular screenings and a healthy lifestyle, vision loss from hypertension can often be Watch
Mint
18-05-2025
- Automotive
- Mint
Ola Electric raised money to expand cell making capacity. But it's still sitting idle
Ola Electric Mobility Ltd's plan to increase the capacity of its cell manufacturing facility has been delayed, exposing it to risks of higher costs, losing incentives and even technology going obsolete. Ola Cell Technologies Private Ltd (OCT), a wholly owned subsidiary of Ola Electric Ltd, began constructing its gigafactory in May 2023 under a four-phase plan to produce lithium-ion cells for electric vehicle batteries. Of the ₹5,500 crore the company raised by issuing fresh shares in August 2024, it had set aside ₹1,227 crore to expand the capacity of its cell manufacturing facility to 6.4 GWh in the second phase by April 2025. However, it has not utilised any money from these funds, suggesting that OCT is far behind the previously disclosed timeline to investors, said Icra Ltd, the monitoring agency of its public issue, in its 15 May report shared by Ola Electric with exchanges. Icra downgraded Ola Cell Technologies BBB- (Negative) in May. 'The battery cell manufacturing segment is highly technologically complex and has significant dependence on imports for sourcing raw materials, which exposes the project to geopolitical and region-specific risks for raw materials," the agency said in its downgrade note. 'OCT, thus, remains exposed to risks of timely execution, demand/offtake, supply chain and technology obsolescence." Also Read: Defender SUV's prices to drop as Jaguar Land Rover plans local assembly In response to Mint's emailed queries, Ola Electric said, 'We have announced the commercial production of our cells beginning Q1 FY26, and are on track to meet the set timelines. Ola Electric will be the first to commercially manufacture lithium-ion cells in India under the government's ACC (advanced chemistry cell) PLI scheme. We continue to have regular discussions with MHI (ministry of heavy industries) regarding updates on our progress and timelines for each of our set milestones." To be sure, other than the expansion of cell factory, the company had also Out of the ₹5500 crore the company raised through fresh issue of shares in August 2024, ₹2671 crore has been utilised while ₹2829 crore remains unutilised. The stated purpose of the fundraise, other than expansion of cell factory capacity, included investment into research and development, general corporate purposes, expenditure for inorganic growth initiatives and repayment of debt. The unutilised funds have been parked by the company in several fixed deposit accounts, earning ₹54 crore so far in interest income. Original road map The company's founder Bhavish Aggarwal had on 15 August 2024 laid down the vision to achieve 20GWh capacity by 2026 as lithium-ion cells are largely imported from China currently. A cluster of cells makes a battery. The capacity of a gigafactory is the total energy that can be produced from cells produced in a year. In phase 1a, the company initially built 1.4 GWh capacity at ₹1,226 crore, which was completed before Ola Electric filed its red herring prospectus (RHP) before listing in August 2024. This capacity was expected to go up to 5 GWh by February 2025 under phase 1b. In an earnings call on 7 February, Aggarwal said the capital expenditure to expand to 5 GWh will come into effect in the current financial year FY26. According to a project cost vetting report submitted with the RHP, phase 2 was to be completed by 30 April to raise the capacity to 6.4 GWh, and targeted to increase that to 20GWh by 2026. According to the RHP, the company was estimated to utilise ₹859 crore in the financial year 2025 and ₹368 crore in fiscal 2026 for the gigafactory expansion. However, as of 15 May, the funds earmarked for the phase 2 remain unused, indicating that the company is way behind the timeline initially conveyed to investors. 'The testing process post completion of a phase can take time as cells are a complex and sensitive technology," said a person aware of the developments. 'A ramp-up post each phase depends on the completion of all testing and other processes of the previous phase." Incentives at stake While Ola Electric had acknowledged in its RHP that the timeline could change depending on the market reality, a delay will have its implications. In 2022, Ola Electric became the first company to be selected under the ₹18,100 crore production-linked incentive plan to indigenise the cell manufacturing ecosystem in India. Under the scheme, Ola had to invest ₹225 crore per GWh of the committed 20GwH capacity, along with 25% value-addition, within two years. The disbursal of the incentives is contingent upon achieving this milestone. Also Read: Hyundai Motor India profit may take a hit in Q4 as sales remain in slow lane However, IFCI Ltd, the project management agency of PLI for cells, wrote a letter to the company in March stating that it had missed the deadline to complete the first milestone. While the company acknowledged the letter to the exchanges, it did not offer any clarity on the timeline. 'The Company is actively engaged with the relevant authorities in this regard and in the process of filing an appropriate response," Ola Electric said in an exchange filing on 4 March. Under the PLI scheme, the company has to build 12GWh of capacity by 2027 to complete the second milestone and achieve 60% value-addition. Ola Electric had previously stated that it would begin the commercial production of its cells in April-June 2025. The status of the project and the changed timeline remain unclear. A person aware of the development said that the company has sought an extension of the deadline under the scheme from the government. Any risk to the incentives can spell problems for the firm, according to analysts. 'One of the reasons for setting up its own Gigafactory was to take advantage of the PLI for advanced chemistry cells, which would have resulted in a 50% reduction in capital employed for setting up 20 GWhr," Rishi Vora of Kotak Institutional Equities wrote in an 18 March note. The company may have to outsource the construction to a third party or else it would find difficult to install 20GWh capacity in the next two to three years, Vora said. The delay in timelines will also have a bearing on the financial health of the firm. A bump on the road to profit 'The slower-than-expected ramp-up of its Gigafactory or lower-than-expected yield will result in higher cash outflow for the company in the coming quarters, which needs to be monitored," Vora wrote. The company earlier anticipated that the integration of cell capacity will be crucial for its margins, which will aid the profitability of the company. 'At a consolidated level, when our battery cell comes in, we will actually have an expansion of margin," Aggarwal said in Q3 FY25 earnings call on 7 February. Also Read: Rich south India struggles to buy cars while northern and western states surge ahead In October-December of FY25, the company's loss widened to ₹564 crore from ₹364 crore from a year earlier. Ola Electric's shares have tumbled nearly 40% in 2025 against a 3.48% rise in Nifty Auto. 'Ideally, when there is a substantial delay in a project, the delay should be flagged," said Amit Tandon, founder and managing director at IiAS. 'If the project has an impact on profitability, it becomes even more important to reveal the reasons behind the delay." Out of the ₹5500 crore the company raised through fresh issue of shares in August 2024, ₹2671 crore has been utilised while ₹2829 crore remains unutilised. The stated purpose of the fundraise, other than expansion of cell factory capacity, included investment into research and development, general corporate purposes, expenditure for inorganic growth initiatives and repayment of debt. The unutilised funds have been parked by the company in several fixed deposit accounts, earning ₹54 crore so far in interest income.
Cision Canada
15-05-2025
- Business
- Cision Canada
Intalight™ Receives CE Mark for Its Progressive DREAM OCT™ Swept Source Imaging Français
SAN JOSE, Calif. and SHANGHAI, May 15, 2025 /CNW/ -- Intalight ™, a company that develops advanced ophthalmic technologies and a leader in Optical Coherence Tomography (OCT) today announced it has received CE mark for its DREAM OCT ™ platform. The CE mark serves as approval by the European Union (EU) to commercialize DREAM OCT, the newest version of OCT. DREAM stands for: Deep imaging depth, Rapid sweeping speed, Extensive scan range, Accurate results, and Multimodal imaging capabilities. The imaging platform provides the highest quality OCT images currently on the market. "Intalight is incredibly proud to receive CE mark approval in Europe for our DREAM OCT," said Intalight chairman and Founder, Shawn Peng. "This achievement allows us to provide ophthalmologists in Europe with state-of-the-art technology that delivers improved results for their patients." DREAM OCT is able to cover an ultrawide field single scan which delivers a 130° OCTA image. DREAM OCT ™ swept-source 12 mm super-depth scanning allows superior imaging of the choroid and retina, and a large portion of the vitreous space. The super-depth anterior scanning capabilities achieves 16.2 mm (in air), allowing for the complete anterior segment from the cornea to the anterior part of the vitreous to be scanned in only one scan. The longer wavelength allows for superior penetration through opacities in either lens or vitreous. "Over the past few years, we've heard from eye care professionals that they need a solution that gets them over the imaging finish line with speed, accuracy and depth," said Intalight CEO and Co-Founder, Bing Li. "DREAM OCT delivers a full set of imaging modalities for the most challenging clinical and research applications for the retina and outperforms everything else HCP's know." Using ultra-wide swept-source technology, DREAM OCT was developed to address the needs of retina specialists, comprehensive ophthalmologists and their patients with highly-detailed imaging capabilities for improved care and results. Currently, more than 160 peer-reviewed papers have utilized findings from DREAM OCT devices. "This is such exciting news for Intalight that there's no more waiting in Europe, and we look forward to being able to provide this innovative solution in the US," remarked Intalight Chief Commercial Officer, Joe Garibaldi. "We look forward to continuing to grow our prestigious network of global institutions and ophthalmologists with our recent CE approval and eventually our FDA approval." As the clinically validated leader of ultra-wide field OCTA, Intalight is currently collaborating with the top retina academic institutions and retina private practices in the United States, Europe, and Asia. About Intalight Intalight Inc. was founded by a group of scientists and industry veterans of Silicon Valley with a core mission to develop the most advanced ophthalmic technologies. There are now three sites in Silicon Valley, Shanghai, and Luoyang. Intalight's Swept-Source Optical Coherence Tomography (OCT) device combines Deep imaging depth, Rapid sweeping speed, Extensive scan range, Accurate lesion detection and Multimodal imaging capabilities, and is abbreviated as DREAM OCT ™. The powerful imaging device has become an indispensable tool for many ophthalmologists in not only their daily clinical use but also their exploration of the research frontiers. To learn more about Intalight and DREAM OCT, please visit our website at and follow us on LinkedIn and Facebook.
